Frequently Asked Questions
ACTIV-6 is a clinical research study testing several repurposed medications that are already approved for other diseases to see if they can help people with mild-to-moderate COVID-19 feel better faster and stay out of the hospital. Repurposed medications are those already approved by the U.S. Food and Drug Administration for other indications.
The study is part of the National Institutes of Health-funded Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) led by the National Center for Advancing Translational Sciences.
The Duke Clinical Research Institute serves as the study’s clinical coordinating center, partnering with Vanderbilt University Medical Center as the study’s data coordinating center.
We have effective treatments for people with mild-to-moderate COVID-19 who are at high risk for hospitalization or death. However, there are not many approved prescription medications that can be taken at home to treat mild-to-moderate symptoms of COVID-19 early in its course to prevent worsening of symptoms and need for hospitalization. This is a vital public health priority, especially with recurring spikes in cases across the globe due to the emergence of new variants.